Analytical Data
-
Gene name
CDK2-CCNA2
- Application
-
Alternative Names
CDKN2; p33(CDK2); Cell division protein kinase 2; p33 protein kinase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P24941
-
Expression Region
Gln5~Pro294
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK2 (Cyclin-Dependent Kinase 2) and CCNA2 (Cyclin A2) are crucial components of the cell cycle regulation machinery, playing pivotal roles in the transition from the G1 phase to the S phase of cell division. Dysregulation of these proteins has been implicated in various cancers, making them attractive targets for therapeutic intervention. The CDK2-CCNA2 complex is essential for the phosphorylation of substrates that regulate DNA synthesis and chromatin remodeling, thereby facilitating cell proliferation. Understanding the structure and function of the CDK2-CCNA2 complex is vital for elucidating the mechanisms underlying cell cycle regulation and its aberrations in tumorigenesis. Research involving the recombinant expression of CDK2 and CCNA2 not only aids in protein characterization but also opens avenues for drug discovery aimed at inhibiting this complex in cancer cells. Furthermore, investigating the interactions between CDK2 and CCNA2 with other cell cycle regulators could provide deeper insights into their cooperative functions and the broader network of cell cycle control. This area of study is particularly significant in the context of developing targeted therapies, as interventions that can precisely disrupt the CDK2-CCNA2 interaction may offer new strategies for cancer treatment, potentially overcoming resistance to conventional therapies. Thus, the study of recombinant CDK2-CCNA2 proteins serves as a foundation for advancing our understanding of cell cycle dynamics and the development of novel cancer therapeutics.
